--- title: "Foghorn Therapeutics (FHTX) news: offering" url: "https://aibio.space/companies/foghorn-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "FHTX offering news: Foghorn Therapeutics cuts at-the-market program to $100 million from $200 million. Foghorn Therapeutics Inc." --- FHTX Foghorn Therapeutics Inc. NASDAQ · United States # Foghorn Therapeutics (FHTX) news FHTX offering news Financings · 2025-03-20 ## [Foghorn Therapeutics cuts at-the-market program to $100 million from $200 million](https://aibio.space/news/foghorn-therapeutics-cuts-market-program-100-million-200-million/) An amendment with TD Cowen cuts the program to $100 million, and the 8-K gives no reason for the cut. The new supplement shows immediate dilution of $3.78 per share at the $4.44 reference price. ## Latest Foghorn Therapeutics news We have not published a story on Foghorn Therapeutics yet. When there is news, it will appear here. ## Foghorn Therapeutics at a glance - **Ticker**: FHTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $68.1 million ### Related companies - [INmune Bio](https://aibio.space/companies/inmune-bio/) NASDAQ: INMB - [C4 Therapeutics](https://aibio.space/companies/c4-therapeutics/) NASDAQ: CCCC - [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) NASDAQ: AXSM - [Immunome](https://aibio.space/companies/immunome/) NASDAQ: IMNM - [First Tracks Biotherapeutics](https://aibio.space/companies/first-tracks-biotherapeutics/) NASDAQ: TRAX - [EHOUSE GLOBAL INC](https://aibio.space/companies/ehouse-global/) OTC: EHOS - [Korsana Biosciences](https://aibio.space/companies/korsana-biosciences/) NASDAQ: KRSA - [MindWalk Holdings](https://aibio.space/companies/mindwalk/) NASDAQ: HYFT ### Also on NASDAQ - [Kura Oncology](https://aibio.space/companies/kura-oncology/) KURA - [Allogene Therapeutics](https://aibio.space/companies/allogene-therapeutics/) ALLO - [Cardiff Oncology](https://aibio.space/companies/cardiff-oncology/) CRDF - [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) TENX - [MiniMed Group](https://aibio.space/companies/minimed/) MMED - [KALA BIO](https://aibio.space/companies/kala-bio/) KALA ## What Foghorn Therapeutics does Foghorn Therapeutics Inc. is a clinical-stage precision therapeutics biotechnology company developing medicines that correct abnormal gene expression by selectively targeting the chromatin regulatory system. The company focuses first on oncology and says the system may also be relevant to immunology and inflammation. Its proprietary Gene Traffic Control platform provides a mechanistic understanding of how the components of the chromatin regulatory system interact, which the company uses to identify, validate and drug targets in that system. Foghorn says it is working on more than seven programs, with one clinical-stage drug candidate in Phase 1 development. Its collaboration with Eli Lilly and Company dates from December 2021 and covers SMARCA2 and an undisclosed oncology target. Lilly has initiated a Phase 1 dose escalation trial of FHD-909 (LY4050784), a selective ATPase inhibitor of SMARCA2, and dosed the first patient in October 2024. The company says the trial is focused on SMARCA4-mutated cancers, with non-small cell lung cancer as the primary patient population. Foghorn's discovery programs also target CBP, EP300 and ARID1B, and the company says it has the potential to file four Investigational New Drug applications over the next two years. | Product or program | What it is | Stage | |---|---|---| | FHD-909 (LY4050784) | Selective ATPase inhibitor of SMARCA2 for SMARCA4-mutated cancers, partnered with Eli Lilly | Phase 1 dose escalation trial initiated by Lilly | | CBP, EP300 and ARID1B programs | Oncology targets for which the company has discovered selective chemical matter | | Summarised from the company's [10-K filed Mar 11, 2026](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/fhtx-20251231.htm). ## Foghorn Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$30.9 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | [$22.6 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | | Research and development | [$85.5 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | [$94.5 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | | Net income (loss) | [-$74.3 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | [-$86.6 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | | Cash from operations | [-$86.1 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | [-$100.4 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | | Cash and equivalents | [$80.9 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026053819/) | [$55.5 million](https://www.sec.gov/Archives/edgar/data/1822462/000162828026016814/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $68.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Foghorn Therapeutics Has Foghorn Therapeutics raised money recently? Our latest story on this, dated Mar 20, 2025: "Foghorn Therapeutics cuts at-the-market program to $100 million from $200 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/foghorn-therapeutics-cuts-market-program-100-million-200-million/). What is the ticker symbol of Foghorn Therapeutics? Foghorn Therapeutics Inc. trades under the ticker FHTX on NASDAQ. Where is Foghorn Therapeutics listed? Foghorn Therapeutics Inc. is listed on NASDAQ. What is the SEC CIK of Foghorn Therapeutics? The SEC Central Index Key (CIK) for Foghorn Therapeutics Inc. is 1822462. Its filings are on SEC EDGAR. How many shares does Foghorn Therapeutics have outstanding? 59,385,315 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Foghorn Therapeutics listed under? Our directory records Foghorn Therapeutics Inc. under United States. What does Foghorn Therapeutics do? Our directory classifies Foghorn Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Foghorn Therapeutics? The ISIN recorded for Foghorn Therapeutics Inc. is US3441741077. Does aibio.space cover Foghorn Therapeutics? aibio.space lists Foghorn Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Foghorn Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Foghorn Therapeutics develop? Foghorn Therapeutics Inc. is a clinical-stage precision therapeutics biotechnology company developing medicines that correct abnormal gene expression by selectively targeting the chromatin regulatory system. The company focuses first on oncology and says the system may also be relevant to immunology and inflammation. What is FHD-909 (LY4050784) from Foghorn Therapeutics? FHD-909 (LY4050784): Selective ATPase inhibitor of SMARCA2 for SMARCA4-mutated cancers, partnered with Eli Lilly Stage: Phase 1 dose escalation trial initiated by Lilly. What is CBP, EP300 and ARID1B programs from Foghorn Therapeutics? CBP, EP300 and ARID1B programs: Oncology targets for which the company has discovered selective chemical matter What was Foghorn Therapeutics's revenue last year? $30.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Foghorn Therapeutics profitable? Foghorn Therapeutics Inc. reported a net loss of $74.3 million for the fiscal year ended Dec 31, 2025, and used $86.1 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Foghorn Therapeutics Members talk about Foghorn Therapeutics (FHTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Foghorn Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-01 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/exhibit991foghornpressrele.htm) 2. 2026-01-12 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1822462/000119312526010520/d65250d424b5.htm) 3. 2025-07-01 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1822462/000162828025033784/fhtx-20250627.htm) 4. 2025-05-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1822462/000162828025021506/ex991pressreleasedatedmay1.htm) 5. 2025-03-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1822462/000162828025014133/foghorn-424b5march2025.htm) 6. 2025-01-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1822462/000162828025002466/fhtx-20250123.htm) 7. 2025-01-24 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1822462/000162828025002469/foghorn-sx3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FHTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-FHTX/). ## SEC filings and registration - **SEC name**: Foghorn Therapeutics Inc. - **CIK**: 1822462 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: FHTX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 500 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139 - **Phone**: 617-586-3100 - **Shares outstanding**: 59,385,315 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/fhtx-20260925.htm) filed 2026-10-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1822462/000162828026053819/fhtx-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/fhtx-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1822462/000162828026045154/fhtx-20260624.htm) filed 2026-06-24 - [10-Q](https://www.sec.gov/Archives/edgar/data/1822462/000162828026031671/fhtx-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1822462/000162828026031669/fhtx-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1822462/000119312526193928/d116077ddef14a.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1822462/000162828026026259/fhtx-20260421.htm) filed 2026-04-21 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001822462), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Foghorn Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FHTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Foghorn Therapeutics Inc. - **Ticker**: FHTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US3441741077 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FHTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/foghorn-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Foghorn Therapeutics (FHTX) news: offering", 2026-10-31, https://aibio.space/companies/foghorn-therapeutics/